Trafalgar Eliminates 481M Potential Common Shares via Preferred Conversion Removal
Summary
Trafalgar International's restated charter eliminates preferred conversion rights that represented 481.4 million potential common shares, while authorizing 2 billion new common shares and locking in Series B's 51% voting control.
Key Events · Corporate Governance and Compliance · GCAN
-
Conversion Rights Eliminated
Series A (7,628,665 shares at 50:1) and Series B (1,000 shares at 100,000:1) conversion rights extinguished, removing 481,433,250 potential common shares from the overhang.
-
Authorized Capital Expanded
New charter authorizes 2,000,000,000 common shares and 20,000,000 preferred shares, up from prior levels — future issuance capacity remains substantial.
-
Series B Voting Control Locked
Series B retains at least 51% of aggregate voting power on a fully diluted basis, with automatic adjustment as the voting base changes; Series A loses its 1.76 votes per share.
-
Series A Rights Stripped
Series A loses general voting rights, liquidation preference, and accrued dividend entitlement; dividends become discretionary.
Analysis · GCAN · Life Sciences
The restated charter removes conversion rights on Series A and Series B preferred stock that could have created 481.4 million common shares — a massive overhang elimination for a company with only 199,153 common shares outstanding. However, the same restatement authorizes 2 billion common shares and 20 million preferred shares, leaving the door open for future dilution. Series B retains permanent 51% voting control, cementing Trafalgar Asset Management's grip on the company. The filing quantifies what the prior 8-K only described qualitatively.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 32.7% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GCAN was trading at $0.47 on OTC in the Life Sciences sector, with a market capitalization of approximately $467.4K. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.